- ECONOMIC IMPACT -

Latest update: 25 January 2022

Hiring prospects for Pharma continue to improve and the Pharma Jobs index grew by 40.6% to date

The momentum of global economic growth is expected to weaken in 2022 amid uncertainty

4.4%

Global growth is expected to be moderate at 4.4% compared to 5.9% in 2021 as per the IMF

7%

Inflation rose by 7% in the US in December 2021 from the previous year

IMPACT OF COVID-19 ON JOBS

- SECTOR IMPACT: PHARMA -

Latest update: 2 February 2022

industry development

1090

Number of disrupted trials due to Covid-19. Suspended trials have begun to recruit participants, but the impact on trials resulting in slow recruitment is still on the rise

45%

Germany has a high booster dose penetration with 45% of people fully vaccinated with a booster while only 18% in Spain are boosted.

SOCIAL MEDIA

Covid-19 lockdown and social distancing measures forced Pharma to rapidly implement new ways of engaging with customers, and promoting their brands and messaging.


This includes increased online marketing on social media like Facebook and LinkedIn, especially as more people are online since the pandemic began.


As per an ongoing poll on Pharmaceutical Technology and Clinical Trials Arena sites, 82% of respondents say the pandemic has led to an increase in the use of social media accounts by Pharma companies

OMICRON IMPACT

Countries like US and Israel have shown decreases in hospitalization following vaccine implementation, but with different initial results, particularly as the Delta and Omicron VoCs have taken hold.


The daily hospitalization rate for both countries stabilized and subsequently decreased; however, vaccine hesitancy and removal of social distancing measures caused increases in hospitalizations.


The increase in hospitalizations was worrisome as it was close to the peak observed early in 2021. The majority of hospitalizations and deaths are occurring in unvaccinated individuals, though the Delta and Omicron variants are easily spread regardless of vaccination status.


With multiple vaccines having shown impressive efficacy, notably for reductions in the need for hospitalization and mortality, the window for utility for COVID-19 therapies may be rapidly contracting. However, this may be offset increased illness caused by the rise of vaccine-resistant variants and shortages of vaccines in certain countries, such as India

Share this article